Dare Bioscience (DARE) EV/EBITDA: History & Chart

Dare Bioscience, Inc.(DARE)

Biotechnology · San Diego, CA

$0.83-0.01 (-1.19%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Dare Bioscience, Inc.

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

San Diego, CA

23 employees

darebioscience.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sabrina Martucci Johnson

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Dare Bioscience, Inc. (DARE)	$12.48M	N/A	N/A	N/A	N/A
Cytosorbents Corporation (CTSO)vs ›	$12.44M	N/A	N/A	N/A	N/A
Tempest Therapeutics, Inc. (TPST)vs ›	$12.58M	N/A	26283.45x	26283.45x	26283.45x
Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›	$12.78M	N/A	N/A	N/A	N/A
Lantern Pharma Inc. (LTRN)vs ›	$12.17M	N/A	N/A	N/A	N/A
Cellectar Biosciences, Inc. (CLRB)vs ›	$12.06M	N/A	N/A	N/A	N/A
Biofrontera Inc. (BFRI)vs ›	$11.93M	N/A	N/A	N/A	N/A
Passage Bio, Inc. (PASG)vs ›	$13.11M	N/A	N/A	N/A	N/A
IRIDEX Corporation (IRIX)vs ›	$11.77M	N/A	133.45x	63.52x	51.85x
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$13.20M	N/A	116.01x	116.01x	116.01x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Dare Bioscience, Inc. (DARE)

$12.48M

N/A

Cytosorbents Corporation (CTSO)vs ›

$12.44M

N/A

Tempest Therapeutics, Inc. (TPST)vs ›

$12.58M